Physician profile
Paul D Schefflein
NPI 1215903380
$1,653.06
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $256.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $445.31 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $184.11 | 2019 | |
| Janssen Pharmaceuticals, INC | $163.56 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $143.56 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.38 | 2019-2020 | |
| Shire North American Group INC | $120.01 | 2019 | |
| Bausch Health US, LLC | $89.83 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $77.95 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $55.93 | 2019 | |
| Neuronetics, INC. | $44.14 | 2019 | |
| Neurocrine Biosciences, INC. | $42.87 | 2019-2020 | |
| Lundbeck LLC | $39.02 | 2019 | |
| Ironshore Pharmaceuticals INC. | $37.35 | 2019 | |
| Vertical Pharmaceuticals, LLC | $32.09 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $29.64 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $11.31 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Schefflein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.